Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, UK.
Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Amyotroph Lateral Scler Frontotemporal Degener. 2023 Feb;24(1-2):63-70. doi: 10.1080/21678421.2022.2102926. Epub 2022 Jul 23.
To investigate whether the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) can provide interval level measurement of disability in Amyotrophic Lateral Sclerosis (ALS), allowing parametric analyses. : Data on the WHODAS 12, 32, and 36-item versions, from 1120 patients studied at one or more time points, were fit to the Rasch model and comparisons made against ALSFRS-R, King's staging, and mortality. Trajectory modeling was undertaken for a newly diagnosed (≤6 months) cohort of 454 individuals. : Total scores for WHODAS 32 and 36-item versions can be converted to interval level measurement suitable for individual clinical use, and the 12-item WHODAS total for group use. The 36-item version is shown to be equivalent to the 32-item version. Expected correlations were seen with King's staging, ALSFRS-R, and EQ-5D-5L. Trajectory analysis of disability (WHODAS 2.0) showed three clearly demarcated groups with differences in King's staging, depressive symptomatology and mortality, but not age. : The WHODAS 2.0 is a brief patient reported outcome measure which can be used to measure disability in ALS. Provided the patient answers all 36 (32 if not working) items, the conversion table produces an interval level estimate for parametric analyses. The different trajectories demonstrated from diagnosis support the concept of a prodromal period, and suggest the WHODAS 2.0 could be used for surveillance of at risk populations, such as those with genetic predisposition.
为了研究世界卫生组织残疾评估表 2.0(WHODAS)是否可以对肌萎缩侧索硬化症(ALS)患者的残疾进行区间水平测量,从而允许进行参数分析。研究数据来自于 1120 名患者,他们在一个或多个时间点接受了 WHODAS 12、32 和 36 项版本的测试。这些数据被拟合到了 Rasch 模型中,并与 ALSFRS-R、King 分期和死亡率进行了比较。对 454 名新诊断(≤6 个月)患者进行了轨迹建模。WHODAS 32 和 36 项版本的总分可以转换为适合个体临床使用的区间水平测量,而 12 项 WHODAS 总分则适用于群体使用。研究结果表明,36 项版本与 32 项版本等效。与 King 分期、ALSFRS-R 和 EQ-5D-5L 均呈现出预期的相关性。对残疾(WHODAS 2.0)的轨迹分析显示,有三个明显区分的组别,在 King 分期、抑郁症状和死亡率方面存在差异,但与年龄无关。WHODAS 2.0 是一种简短的患者报告结局测量工具,可用于测量 ALS 患者的残疾程度。如果患者回答了所有 36 项(如果不工作则为 32 项)问题,则转换表将为参数分析提供区间水平估计。从诊断开始就表现出的不同轨迹支持前驱期的概念,并表明 WHODAS 2.0 可用于监测高危人群,如具有遗传易感性的人群。